Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Former England striker Gary Lineker sticks to a strict 'one meal a day' diet, which he credits with keeping him in shape. Lineker, 64, has hosted BBC’s stalwart Match of the Day for 25 years ...

More often than not, the answer lies in our diet. But it seems that what we consume can impact our lives in more ways than we might imagine. A neuroscientist has revealed that simply adding one ...

One Piece Fan Letter, a Special released recently, was very well received by all fans. The special ended up being rated as the best TV Movie or Special on Letterboxd. This ranking is specifically ...

The UK's "most desirable" towns have been named, and in one of them, houses cost more than £1.4million on average. The list was compiled by The Telegraph, the newspaper commissioning estate agent ...

Nick Fuller, Clinical Trials Director in the Department of Endocrinology at the University of Sydney said there are a number of reasone ... and with an interval weight loss approach.

Indianapolis-based Eli Lilly and Co. is projecting approval of its experimental weight-loss pill as soon as early 2026, CEO Dave Ricks said, one of several in a new generation of the popular drugs.